Wall Street analysts predict that Aldeyra Therapeutics Inc (NASDAQ:ALDX) will post earnings per share of ($0.32) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Aldeyra Therapeutics’ earnings, with estimates ranging from ($0.33) to ($0.30). Aldeyra Therapeutics reported earnings of ($0.36) per share in the same quarter last year, which would suggest a positive year over year growth rate of 11.1%. The company is expected to report its next quarterly earnings report on Thursday, March 29th.
According to Zacks, analysts expect that Aldeyra Therapeutics will report full-year earnings of ($1.35) per share for the current year, with EPS estimates ranging from ($1.37) to ($1.33). For the next fiscal year, analysts expect that the firm will post earnings of ($1.43) per share, with EPS estimates ranging from ($1.53) to ($1.24). Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that that provide coverage for Aldeyra Therapeutics.
ALDX has been the subject of several analyst reports. Zacks Investment Research raised shares of Aldeyra Therapeutics from a “hold” rating to a “buy” rating and set a $7.50 price objective for the company in a research note on Tuesday, January 2nd. Seaport Global Securities initiated coverage on shares of Aldeyra Therapeutics in a research note on Friday, January 26th. They issued a “buy” rating and a $13.00 price objective for the company. Canaccord Genuity reissued a “buy” rating and issued a $27.00 price objective on shares of Aldeyra Therapeutics in a research note on Tuesday. Finally, ValuEngine raised shares of Aldeyra Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $16.79.
Shares of Aldeyra Therapeutics (NASDAQ:ALDX) traded down $0.15 during midday trading on Wednesday, reaching $8.70. 27,758 shares of the company’s stock traded hands, compared to its average volume of 105,301. The company has a current ratio of 20.35, a quick ratio of 20.35 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $170.15, a P/E ratio of -6.21 and a beta of 0.46. Aldeyra Therapeutics has a twelve month low of $3.80 and a twelve month high of $11.90.
ILLEGAL ACTIVITY NOTICE: This article was originally published by American Banking News and is the property of of American Banking News. If you are reading this article on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2018/03/14/aldeyra-therapeutics-inc-aldx-expected-to-announce-earnings-of-0-32-per-share.html.
About Aldeyra Therapeutics
Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.